Mark Massaro's questions to Neogenomics Inc (NEO) leadership • Q1 2025
Question
Mark Massaro of BTIG asked for clarity on how the partnership with Adaptive Biotechnologies will be additive to NeoGenomics, including revenue potential, and the strategic benefit. He also inquired about the expected timeline for receiving MolDX reimbursement coverage for the PanTracer liquid biopsy test.
Answer
President & COO Warren Stone explained the Adaptive partnership is synergistic, as Adaptive will promote Neo's COMPASS test in academic centers while Neo will offer Adaptive's clonoSEQ in the community setting, driving incremental COMPASS volume. CEO Anthony Zook added that the key patient benefit is a single, less painful sample draw for both diagnosis and MRD testing. CIO Andrew Lukowiak estimated that a MolDX decision for PanTracer could come by year-end, following a standard review process of about two turns.